and alogliptin 25 mg treated vs controls demonstrated a significant reduction in HbA1c in patients treated with either dose of alogliptin (SMD = −0.81; 95% CI, -1.11 to −0.51; SMD= −0.98 ...
In agreement with a previous meta-analysis, that was conducted on DPP-4 inhibitors including four studies on alogliptin, [27] this meta-analysis has demonstrated a significant reduction of HbA1c ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback